纳武利尤单抗致免疫相关性肾毒性文献回顾性分析 董俊丽.pdf

中国医院药学杂志
Chinese Journal of Hospital Pharmacy
ISSN 1001-5213,CN 42-1204/R
性肾炎。29 例患者经停药和（或）对症治疗后痊愈或好转，4 例患者死亡。结论：纳武利尤单抗治疗过程中需关
注患者的临床症状及肾功能，鉴别其可能导致的免疫相关性肾损伤，及时根据严重程度分级处理，并警惕再次给药后
可能发生的复发风险。
关键词 纳武利尤单抗；免疫相关性肾毒性；肾炎
中图分类号 文献标志码 A
Literature analysis of immune-related nephritis induced by Nivolumab
DONG Jun-li1, LI Lu-lu1, ZHANG Shao-hui1, HU Song1, ZHONG Min-yu2
(1. Department of Pharmacy，2. Department of Oncology，Wuhan Hospital, Hubei Wuhan 430022, China)
Abstract OBJECTIVE To analyze clinical characteristics of immune-related nephrotoxicity induced by Nivolizumab, and
to provide reference for rational application of Nivolumab in clinic. METHODS CNKI, VIP, Wanfang, PubMed and Web of
Science databases were searched for immune-related nephrotoxicity induced by Nivolumab from March 2015 to December
2021, and were further analyzed statistically. RESULTS A total of 33 cases of immune-related nephrotoxicity induced by
Nivolumab were identified and included. The median occurrence time of immune-related nephrotoxicity induced by
Nivolumab was (±) months. The main clinical charateristics were limb fatigue and edema with increased creatinine,
with or without albuminuria. The